TaiRx

TaiRx Gross Margin

The Gross Margin of TaiRx (6580.TWO) as of Oct 17, 2026 is 36.19 %. In the previous year, Gross Margin was 16.33 % — a change of 121.58% (higher).

Gross Margin

36.19 %

YoY

121.58%

Last updated:

Gross Margin of TaiRx is 2025 36.19 % . Gross Margin of TaiRx was 2024 16.33 % . It decreases by 121.58% higher compared to the previous year.

TaiRx's gross margin stands at 36.2%, down from 47.6% several years earlier.

The TaiRx Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
44.97 TWD
Jan 1, 2019
47.62 TWD
Jan 1, 2020
47.63 TWD
Jan 1, 2021
47.62 TWD
Jan 1, 2022
57.09 TWD
Jan 1, 2023
47.99 TWD
Jan 1, 2024
16.33 TWD
Jan 1, 2025
36.19 TWD
The TaiRx Gross Margin history
YEARGross MarginYoY
36.19 %+121.58%
16.33 %-65.97%
47.99 %-15.93%
57.09 %+19.88%
47.62 %-0.03%
47.63 %+0.02%
47.62 %+5.90%
44.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

Gross Margin of TaiRx is 36.19 % in 2025.

Gross Margin of TaiRx changed from 16.33 % to 36.19 %, representing a 121.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin TaiRx since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's TaiRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — TaiRx

All Key Metrics — TaiRx